



Prior Authorization
JOHNS HOPKINS HEALTHCARE (MEDICAID) Vyndaqel - Priority Partners MCO
This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Johns Hopkins Healthcare at 1-410-424-4607 . Please contact Johns Hopkins Healthcare at 1-888-819-1043 with questions regarding the Prior Authorization process.
When conditions are met, we will authorize the coverage of Vyndaqel - Priority Partners MCO.

Drug Name (select from list of drugs shown) Vyndaqel (tafamidis meglumine)

Quantity	Frequency	Strength
Route of Administration	Expected Length of Therapy	

Patient Information	
Patient Name:	_____
Patient ID:	_____
Patient Group No.:	_____
Patient DOB:	_____
Patient Phone:	_____

Prescribing Physician	
Physician Name:	_____
Physician Phone:	_____
Physician Fax:	_____
Physician Address:	_____
City, State, Zip:	_____

Diagnosis: _____	ICD Code: _____
-------------------------	------------------------

Comments: _____

Please circle the appropriate answer for each question.	
1. Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.	
[If yes, skip to question 10.]	
2. Does the patient have a documented diagnosis of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)?	<input type="checkbox"/> Y <input type="checkbox"/> N

NOTE: Submission of medical records is required.	
[If no, no further questions.]	
3. Is the diagnosis of wild type hereditary transthyretin-mediated amyloidosis (ATTR-CM) supported with documentation for one of the following: A) tissue biopsy supporting histologic confirmation of ATTR amyloid deposits, or B) genetic testing that shows the patient has a hereditary variant in the TTR mutation (such as Val122Ile, or Val30Met mutations)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, skip to question 5.]	
4. Is there documentation for all of the following: A) grade 2 or 3 cardiac retention of radionuclide-tagged bisphosphonate on bone scintigraphy (99mTc-DPD/99mTc-PYP/99mTc-HMDP), B) absence of a detectable monoclonal protein in serum and urine immunofixation electrophoresis (IFE) and serum free light chain (sFLC) assay, and C) echocardiogram, electrocardiogram, or cardiac magnetic resonance imaging that suggest cardiac amyloidosis?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
5. Does the patient have either of the following: A) New York Heart Association (NYHA) Functional Class IV heart failure symptoms, or B) a history of liver or heart transplant?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, no further questions.]	
6. Is there documentation that the patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure symptoms?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
7. Does the patient have documented clinical signs and symptoms of cardiomyopathy (such as dyspnea, peripheral edema, hepatomegaly, ascites, etc.)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
8. Is or has the prescriber consulted with a cardiologist?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
9. Is the patient 18 years of age or older?	<input type="checkbox"/> Y <input type="checkbox"/> N
[No further questions.]	
10. Is there documentation showing the patient continues to have New York Heart Association (NYHA) Functional Class I, II, or III heart failure, but has experienced clinical improvements from treatment?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	

[If no, no further questions.]

11. Is the patient's clinical improvement evidenced by at least one of the following: A) improvement of clinical signs and symptoms, B) slowing of cardiomyopathy disease progression, C) increased quality of life activities, D) reduced hospital admissions related to the condition?

Y N

NOTE: Submission of medical records is required.

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date